Sanofi begins construction of new insulin manufacturing facility in Frankfurt

Sanofi has broken ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The plant will bring a new generation of insulin production to one of the company’s largest integrated research and manufacturing sites, strengthening its ability to supply insulin reliably to millions of people with diabetes worldwide.

Hesse’s Prime Minister Boris Rhein and Frankfurt Mayor Mike Josef attended the ceremony. They were joined by Belén Garijo, chief executive officer of Sanofi, Brendan O’Callaghan, executive vice president for manufacturing and supply and chairman of the supervisory board of Sanofi in Germany, and Madeleine Roach, country president of Sanofi in Germany.

Garijo said millions of people depend on insulin every day and that Sanofi’s commitment to them is long term. She said the facility is an investment in the next generation of insulin manufacturing in Europe, built on more than a century of expertise and a strong industrial presence in Frankfurt. She added that keeping the right conditions for investment and innovation will be essential to Europe’s future competitiveness.

The facility will occupy 36,000 square metres of the Frankfurt BioCampus, roughly the size of five football pitches. It is designed to meet the highest standards of quality and automation and will use advanced digital technologies and artificial intelligence across its manufacturing and quality processes. Full production of insulin active pharmaceutical ingredient is planned for 2032, once the plant is fully licensed. Once running, it is expected to be among the largest and most advanced insulin manufacturing sites in Europe and a key part of Sanofi’s global insulin supply network.

The Frankfurt BioCampus already covers the full insulin manufacturing chain, from active ingredient production to filling, device assembly and packaging. Around 4,000 employees work on insulin there, and about 20 insulin products are supplied from the site.

More than 500 million people worldwide live with diabetes, and the number is expected to pass 800 million by 2050. Sanofi says reliable long term insulin supply will stay essential as the global supply landscape changes. The company currently supplies insulin to about 15 million people in more than 100 countries each year, and says the new facility will help ensure its manufacturing network can serve patients for decades.

Sanofi announced its plans for the Frankfurt facility in August 2024. In September 2026, the European Commission approved public support from the German federal government, the State of Hesse and the City of Frankfurt under the European Union’s state aid framework.

---

---

Related Topics and Keywords

BioCampus, Biopharma, biopharma news, Diabetes, Diabetes Care, Frankfurt, Germany, healthcare, Hesse, insulin, Life Sciences, manufacturing, pharma, Pharma Manufacturing, Sanofi